Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 14/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | BRD4 | O60885 | 1/20 | 0.74 |
| ▸ | IKBKB | O14920 | 1/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.74 |
| ▸ | MAOA | P21397 | 1/20 | 0.74 |
| ▸ | MAOB | P27338 | 1/20 | 0.74 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31322174 | 0.88 | TERT (1.00) | TERTKDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL4649959 | 0.88 | TERT (1.00) | TERTKDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL6618692 | 0.87 | TERT (0.76) | TERTKDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL6613794 | 0.86 | TERT (0.79) | TERTKDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL35318 | 0.85 | TERT (1.00) | TERTKDM4EALDH1A1CYP3A4MAPT | |
| 7,8-Dihydroxyflavone SCHEMBL29374601 | 0.85 | TERT (1.00) | TERTKDM4EALDH1A1CYP3A4MAPT | |
| 7,8-Dihydroxyflavone SCHEMBL419316 | 0.85 | TERT (1.00) | TERTKDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL6617302 | 0.85 | TERT (0.76) | TERTKDM4EALDH1A1CYP3A4MAPT | |
| 7,8-Dihydroxyflavone SCHEMBL21852713 | 0.84 | TERT (0.97) | TERTKDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL6804531 | 0.83 | TERT (0.81) | TERTKDM4EALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373244-A2 | SUBSTITUTED BENZOPYRANONES AS TELOMERASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-02 | — | — | EP | claimed |
| WO-2002074036-A2 | SUBSTITUTED BENZOPYRANONES AS TELOMERASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2002-09-26 | — | — | WO | claimed |
| EP-2579870-B1 | TRKB AGONISTS AND METHODS OF USE | UNIV EMORY (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9504674-B2 | TrkB agonists and methods of use | EMORY UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-25 | — | — | US | disclosed |
| US-9029561-B2 | TRKB agonists and methods of use | EMORY UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| US-20040063665-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-01 | — | — | US | disclosed |
| EP-1373244-A2 | SUBSTITUTED BENZOPYRANONES AS TELOMERASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-02 | — | — | EP | disclosed |
| US-20020160983-A1 | Substituted benzopyranones as telomerase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2002-10-31 | — | — | US | disclosed |
| WO-2002074036-A2 | SUBSTITUTED BENZOPYRANONES AS TELOMERASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | NTRK2, BDNF, NTRK1 | TERT 2930/4885KDM4E 1353/4885ALDH1A1 1116/4885 |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NTRK2, BDNF, NTRK1 | TERT 2908/4885KDM4E 1150/4885ALDH1A1 1274/4885 |
| US-20020160983-A1 | Substituted benzopyranones as telomerase inhibitors | TERT, TERF2, TERF2IP | TERT 1/4885KDM4E 908/4885ALDH1A1 1247/4885 |
| US-20040063665-A1 | Substituted benzopyranones as telomerase inhibitors | TERT, TERF2, TERF2IP | TERT 1/4885KDM4E 889/4885ALDH1A1 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.